tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Latent Tuberculosis D055985 1 associated lipids
Nephritis, Hereditary D009394 1 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Rectal Diseases D012002 1 associated lipids
Citrullinemia D020159 1 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Sweet Syndrome D016463 1 associated lipids
Optic Neuritis D009902 1 associated lipids
Central Nervous System Viral Diseases D020805 1 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Intertrigo D007402 1 associated lipids
Miller Fisher Syndrome D019846 1 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Hepatic Insufficiency D048550 1 associated lipids
Lung Abscess D008169 1 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Hypoplastic Left Heart Syndrome D018636 1 associated lipids
Mite Infestations D008924 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Leukoplakia D007971 1 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Lymphocele D008210 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Malacoplakia D008287 1 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Lichen Nitidus D017513 1 associated lipids
Incontinentia Pigmenti D007184 2 associated lipids
Vitiligo D014820 2 associated lipids
Hypopigmentation D017496 2 associated lipids
Tumor Lysis Syndrome D015275 2 associated lipids
Rectal Fistula D012003 2 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Eye Infections, Fungal D015821 2 associated lipids
Pruritus Ani D011538 2 associated lipids
Deglutition Disorders D003680 2 associated lipids
Discitis D015299 2 associated lipids
Fox-Fordyce Disease D005588 2 associated lipids
Collagen Diseases D003095 2 associated lipids
Multiple Pulmonary Nodules D055613 2 associated lipids
Cholecystolithiasis D041761 2 associated lipids
Brachial Plexus Neuritis D020968 2 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Vestibular Diseases D015837 2 associated lipids
Paresis D010291 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Dumont FJ et al. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. 1990 J. Immunol. pmid:1688572
Woo J et al. Immunosuppressive activity of FK-506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal. 1990 Clin. Exp. Immunol. pmid:1689226
Dumont FJ et al. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. 1990 J. Immunol. pmid:1689353
Brown Z and Neild GH FK-506 and haemolytic uraemic syndrome. 1990 Lancet pmid:1689442
Thomas J et al. The immunosuppressive action of FK506. In vitro induction of allogeneic unresponsiveness in human CTL precursors. 1990 Transplantation pmid:1689518
Ericzon BG et al. Pancreaticoduodenal allotransplantation with FK 506 in the cynomolgus monkey. 1990 Transplant. Proc. pmid:1689905
Murase N et al. Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. 1990 Transplant. Proc. pmid:1689906
Hoffman AL et al. The effect of FK 506 on small intestine allotransplantation in the rat. 1990 Transplant. Proc. pmid:1689907
Lee KK et al. Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy. 1990 Transplant. Proc. pmid:1689908
Ueda Y et al. Induction of graft acceptance after dog kidney or liver transplantation. 1990 Transplant. Proc. pmid:1689909
Ohara K et al. Toxicologic evaluation of FK 506. 1990 Transplant. Proc. pmid:1689910
Nalesnik MA et al. The effect of FK 506 and CyA on the Lewis rat renal ischemia model. 1990 Transplant. Proc. pmid:1689911
Francavilla A et al. FK 506 as a growth control factor. 1990 Transplant. Proc. pmid:1689912
Mazzaferro V et al. Studies of the hepatotrophic qualities of FK 506 and CyA. 1990 Transplant. Proc. pmid:1689913
Standaert RF et al. Molecular cloning and overexpression of the human FK506-binding protein FKBP. 1990 Nature pmid:1696686
Tropschug M et al. Isolation and sequence of an FK506-binding protein from N. crassa which catalyses protein folding. 1990 Nature pmid:1696687
Randall T New antirejection drugs anticipated. 1990 JAMA pmid:1696999
Metcalfe S et al. FK 506 and cyclosporine A: early effects on activation and gene induction in mouse spleen cells. 1990 Transplant. Proc. pmid:1697107
Morris RE et al. A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. 1990 Transplant. Proc. pmid:1697111
Woo J et al. Flow cytometric analysis of lymphocyte populations and activation antigen expression in blood and lymphoid tissues of FK 506-treated rats. 1990 Transplant. Proc. pmid:1697112
Woo J et al. Effects of FK 506 and low concentration cyclosporine on human lymphocyte activation antigen expression: a flow cytometric analysis. 1990 Transplant. Proc. pmid:1697113
Propper DJ et al. Low-dose FK 506 inhibits sensitisation after blood transfusions. 1990 Transplant. Proc. pmid:1697114
Tiebosch A et al. Side effects of FK 506 in cynomolgus monkeys: a histopathologic study. 1990 Transplant. Proc. pmid:1697115
Suzuki S et al. In vivo 31P nuclear magnetic resonance findings on heterotopically allografted hearts in rats treated with a novel immunosuppressant, FK506. 1990 Heart Vessels pmid:1699922
Bierer BE et al. Probing immunosuppressant action with a nonnatural immunophilin ligand. 1990 Science pmid:1700475
Murase N et al. FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. 1990 Transplantation pmid:1700504
Burke MD et al. Inhibition of the metabolism of cyclosporine by human liver microsomes by FK506. 1990 Transplantation pmid:1700507
Wicker LS et al. Suppression of B cell activation by cyclosporin A, FK506 and rapamycin. 1990 Eur. J. Immunol. pmid:1700753
Sigal NH et al. Observations on the mechanism of action of FK-506. A pharmacologic probe of lymphocyte signal transduction. 1990 Biochem. Pharmacol. pmid:1700909
Hara S et al. The effects of a new immunosuppressive agent, FK506, on the glomerular injury in rats with accelerated nephrotoxic serum glomerulonephritis. 1990 Clin. Immunol. Immunopathol. pmid:1700936
Murase N et al. Effect of FK 506 on spontaneous diabetes in BB rats. 1990 Diabetes pmid:1700959
Mochizuki M and Kawashima H Effects of FK506, 15-deoxyspergualin, and cyclosporine on experimental autoimmune uveoretinitis in the rat. 1990 Autoimmunity pmid:1717007
Ni M et al. FR900506 (FK506) and 15-deoxyspergualin (15-DSG) modulate the kinetics of infiltrating cells in eyes with experimental autoimmune uveoretinitis. 1990 Autoimmunity pmid:1717008
Collier SJ Immunosuppressive drugs. 1989-1990 Curr. Opin. Immunol. pmid:2484794
McCauley J et al. Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. 1989 Dec 23-30 Lancet pmid:2481200
Sakamoto K et al. Analysis of long-term acceptance of xenografts in rats induced by short-term administration of FK506. 1989 Transplant. Proc. pmid:2468222
Nakajima K et al. Effects of 15-deoxyspergualin and FK506 on the histology and survival of hamster-to-rat cardiac xenotransplantation. 1989 Transplant. Proc. pmid:2468223
Ochiai T et al. Comparative studies on the immunosuppressive activity of FK506, 15-deoxyspergualin, and cyclosporine. 1989 Transplant. Proc. pmid:2468228
Yasunami Y et al. Effects of a novel immunosuppressive agent, FK-506, on islet allograft survival in the rat. 1989 Transplant. Proc. pmid:2468234
Kobayashi C et al. Suppression of corneal graft rejection in rabbits by a new immunosuppressive agent, FK-506. 1989 Transplant. Proc. pmid:2468254
Kuroki H et al. Experimental studies of vascularized allogeneic limb transplantation in the rat using a new immunosuppressive agent, FK-506: morphological and immunological analysis. 1989 Transplant. Proc. pmid:2468255
Arai K et al. Prolonged limb allograft survival with short-term treatment with FK-506 in rats. 1989 Transplant. Proc. pmid:2468256
Ishibashi M et al. Immunopharmacologic effects of immunosuppressive agents explored by a new effector monocyte generation assay. 1989 Transplant. Proc. pmid:2469228
Starzl TE et al. Liver transplantation: an unfinished product. 1989 Transplant. Proc. pmid:2469232
Hatanaka H et al. FK-506 related compounds produced by Streptomyces tsukubaensis No. 9993. 1989 J. Antibiot. pmid:2470720
Francavilla A et al. Augmentation of rat liver regeneration by FK 506 compared with cyclosporin. 1989 Lancet pmid:2479802
Walliser P et al. Inhibition of murine B-lymphocyte proliferation by the novel immunosuppressive drug FK-506. 1989 Immunology pmid:2480331
Aoki M et al. [Histological observations of immunosuppressive effects of FK-506 in canine lung allotransplantation]. 1989 Bull Chest Dis Res Inst Kyoto Univ pmid:2482787
Kay JE and Benzie CR T lymphocyte activation through the C28 pathway is insensitive to inhibition by the immunosuppressive drug FK-506. 1989 Immunol. Lett. pmid:2483716
Leonard DK et al. Toxicity of FK-506 in human fetal pancreas. 1989 Diabetes pmid:2463195